Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward (Initiator)

• ClinicalTrials.gov Identifier: NCT04871958
• Recruitment Status: Enrolling by invitation
• First Posted: May 4, 2021
• Last Update Posted: May 4, 2021
• Sponsor: Federico II University
• Information provided by (Responsible Party): Giovanni Annuzzi, Federico II University

Study Description

Brief Summary:

During the current Covid-19 pandemic, many hospitals worldwide have been overwhelmed and strategies based on new technologies have been considered to improve the outcomes in patients with diabetes and Covid-19 and to prevent healthcare workers' exposure. Point-of-care blood glucose measurements, with the need of frequent and intermittent blood glucose testing and the associated time burden for hospital staff workers, have evident limitations. To this respect, continuous glucose monitoring (CGM) might represent an effective tool in hospitalized patients. The latest CGM devices have alarms alerting clinicians (or patients) to abnormal blood glucose values. Furthermore, CGMs not requiring calibration with capillary glucose testing have the potential to decrease both nurse and patient burden.

Insulin therapy is recommended in hospitalized patients with diabetes and Covid-19, conventionally by multiple daily insulin injections, i.e., rapid-acting insulin before meals and long-acting insulin once-a-day. Such a complex regimen demands also multiple daily fingerstick for glucose control. Use of continuous subcutaneous insulin infusion in hospital has been considered, and simple, less sophisticated pumps might be appro¬priate for prompt use by healthcare providers not specialized in diabetes treatment. V-Go® is a skin-patch insulin delivery device to be replaced every 24 h. It is fully mechanical, without tubing or electronics, and does not require any programming. It delivers a continuous basal infusion of rapid-acting insulin and allows for additional units before meals.

Therefore, the implementation of CGM and automated insulin infusion in Covid-19 hospitals has the potential to improve clinical outcomes, protect frontline healthcare workers, and preserve personal protective equipment. However, because only observational retrospective data for CGM use and no data on insulin pump use are currently available, randomized controlled trials are needed to determine whether using these technologies in hospital is of significant help.

The aims of this study are to explore, in patients with diabetes in COVID-19 wards, whether using continuous glucose monitoring with a glucose telemetry system and/or using a disposable insulin pump may improve blood glucose control and Covid-19 outcomes, and facilitate diabetes management.

Condition or disease	Intervention/treatment	Phase
Diabetes Mellitus; Covid19	Device: Continuous glucose monitoring (CGM, Dexcom G6)	Not Applicable

Detailed Description:

Both hyperglycaemia and hypoglycaemia are associated with poor outcomes in patients with COVID-19. In these patients, severe hyperglycaemia after hospital admission is a strong predictor of death among non-ICU patients and inpatient hyperglycaemia is associated with an increased risk of death even in patients without diabetes. However, there is no current indication for blood glucose targets in hospitalized patients with COVID-19.

During the current COVID-19 pandemic, many hospitals worldwide have been overwhelmed and diabetes care centers are considering strategies based on technology to improve the outcomes in patients with diabetes and COVID-19 and to prevent healthcare workers' exposure, while optimizing the use of personal protective equipment (PPE). Point-of-care (POC) blood glucose measurements, in the context of a Covid-19 ward, with the need of frequent and intermittent blood glucose testing and the associated time burden for nursing and ancillary hospital staff workers, have shown significant limitations. From this point of view, continuous glucose monitoring (CGM) might represent an effective tool for blood glucose tracking in hospitalized patients. Consistently, in April 2020 the FDA authorized the use of CGM in patients with Covid-19, making CGM a potential favoured option in these patients. Companies, like Abbott and Dexcom, have supplied CGM systems to hospitals and provided education to use their devices effectively. The latest generation of CGM devices have alarms that can alert clinicians (or patients) to abnormal blood glucose values. Furthermore, CGMs that no longer require calibration with POC glucose testing (factory-calibrated) have the potential to decrease both nurse and patient burden associated with frequent POC glucose testing in the hospital.

Healthcare professional societies recommend insulin therapy in hospitalized patients with diabetes, and this holds especially true in Covid-19 patients. The conventional treatment approach involves multiple daily insulin injections (MDI) and includes the administration of rapid-acting insulin analogues before meals and a long-acting insulin analogue once a day. Such a complex regimen demands also multiple daily POC fingerstick for glucose control. Automated insulin delivery including CSII (continuous subcutaneous insulin infusion) has been considered in the hospital setting. In type 2 diabetes, insulin pump therapy induces better glycaemic control than MDI. A likely mechanism for the improved control on CSII is that the traditional large bolus injections of long-acting insulin required during MDI in type 2 diabetes are more erratically absorbed than the slow rapid-acting insulin infusion of CSII. In this respect, the same dose of insulin given via the basal rate of CSII induced better glycaemic control and higher circulating serum insulin concentrations than when given as an injection of long-acting insulin.

However, starting and managing CSII in the hospital setting by personnel and patients not adequately trained might represent a challenging barrier in a Covid-19 ward. Therefore, simpler and less sophisticated pumps might become more appropriate for prompt use by healthcare providers not specialized in diabetes treatment. V-Go® (Zealand Pharma A/S, Denmark) is a wearable insulin delivery device, fully mechanical without tubing or electronics, that does not require any programming. It delivers a continuous basal infusion of rapid-acting insulin (20, 30, or 40 units/24 h) and allows for up to 36 additional units for mealtime dosing in 2-unit increments. V-Go® is filled with fast-acting insulin and is worn like a patch on the skin using a hypoallergenic and latex-free adhesive. It is designed to be replaced every 24 h and is fully disposable. The implant of the device is easily obtained by the push of a button that inserts a 4.6-mm, 30-gauge stainless steel needle subcutaneously and starts the delivery of the continuous pre-set basal rate of insulin. Mealtime bolus insulin doses are administered on-demand by pressing the bolus-ready button and the bolus delivery button. Previous studies showed that switching patients from traditional insulin delivery modes to V-Go® was associated with significantly improved glycaemic control.

Therefore, the implementation of CGM and insulin infusion technologies in Covid-19 hospitals has the potential to improve clinical outcomes, help to protect frontline healthcare workers, and preserve PPE. However, because only observational retrospective data for CGM use and no data on insulin pump use are currently available, randomized controlled trials are needed to determine whether use of CGM and CSII systems in the hospital can be of significant help.

The aims of this study are to explore whether in patients hospitalized in COVID-19 non-ICU:

1. the use of CGM with a glucose telemetry system, compared with intermittent capillary blood glucose monitoring and/or
2. the use of a disposable insulin pump, compared with a conventional multiple daily insulin injection, may improve blood glucose control and COVID outcomes in patients with type 2 or secondary diabetes mellitus and facilitate diabetes management by health care providers.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 66 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment

Intervention Model Description

All patients admitted at the COVID-19 non-ICU with a diagnosis of Type 2 or Secondary diabetes mellitus (DM) for whom intensive insulin therapy (basal plus at least two boluses) is indicated are eligible for the primary study.

After stratification for admission ward, type of DM (known/unknown type 2, steroid use), age, and gender, participants will be randomized to one of the following interventions:

1. Real-time CGM, multiple daily injections managed according to CGM
2. Real-time CGM, insulin pump (V-Go) managed according to CGM
3. Blind CGM, multiple daily injections managed according to POC glucose testing.

• Masking: Single (Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward
• Actual Study Start Date: March 19, 2021
• Estimated Primary Completion Date: August 31, 2021
• Estimated Study Completion Date: September 30, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: rtCGM/MDI; Real-time CGM, insulin therapy by multiple daily injections managed according to CGM	Device: Continuous glucose monitoring (CGM, Dexcom G6); The Dexcom G6 sensor will be placed on the back of the upper arm at admission and changed after 10 days. In the participants randomized to Real-time CGM, glucose values will be transmitted through Bluetooth to a mobile phone at the bedside. From this phone data are transmitted to a tablet in the nursing station. In the blinded CGM group, sensor readings will be blinded to patient and healthcare providers. The MDI groups will be managed with basal/bolus insulin regimen, as clinically indicated. V-Go will be placed on the abdomen each morning. Insulin-naïve patients randomized to the V-Go system will start at the lowest basal rate (20 UI/24h). On daily basis, expert diabetologists will retrospectively review CGM data and provide indications for insulin therapy adjustments.; Other Name: Continuous subcutaneous insulin infusion (V-Go)
Experimental: rtCGM/V-Go; Real-time CGM, insulin therapy by V-Go insulin pump managed according to CGM	Device: Continuous glucose monitoring (CGM, Dexcom G6); The Dexcom G6 sensor will be placed on the back of the upper arm at admission and changed after 10 days. In the participants randomized to Real-time CGM, glucose values will be transmitted through Bluetooth to a mobile phone at the bedside. From this phone data are transmitted to a tablet in the nursing station. In the blinded CGM group, sensor readings will be blinded to patient and healthcare providers. The MDI groups will be managed with basal/bolus insulin regimen, as clinically indicated. V-Go will be placed on the abdomen each morning. Insulin-naïve patients randomized to the V-Go system will start at the lowest basal rate (20 UI/24h). On daily basis, expert diabetologists will retrospectively review CGM data and provide indications for insulin therapy adjustments.; Other Name: Continuous subcutaneous insulin infusion (V-Go)
No Intervention: blindCGM/MDI; Blind CGM, insulin therapy by multiple daily injections managed according to standard care (capillary glucose measurements)

Outcome Measures

Primary Outcome Measures :

1. Blood glucose Time-In-Range (TIR) during hospital stay [ Time Frame: From date of randomization until the date of discharge from the hospital ward up to 2 months ]
   Percentage of time spent within the interval of blood glucose between 70 and 180 mg/dl

Secondary Outcome Measures :

1. Hypoglycemia events [ Time Frame: From date of randomization until the date of discharge from the hospital ward up to 2 months ]
   Number and duration of hypoglycemias
2. Change in fructosamine [ Time Frame: Date of admission and day of discharge from the hospital ward ]
   Change in fructosamine level during hospital stay
3. Change in COVID-19 severity score [ Time Frame: Date of admission and day of discharge from the hospital ward ]
   Scores MEWS and SCARP
4. Length of stay in the hospital ward [ Time Frame: From date of randomization until the date of discharge from the hospital ward up to 2 months ]
   Duration of stay
5. Accesses to the isolation room [ Time Frame: From date of randomization until the date of discharge from the hospital ward up to 2 months ]
   Number of healthcare workers accesses to the isolation room (capillary blood glucose, insulin injections, other)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• All patients admitted at the COVID-19 non-ICU with a diagnosis of Type 2 or Secondary diabetes mellitus (DM) for whom intensive insulin therapy (basal plus at least two boluses) is indicated are eligible for the study.

Exclusion Criteria:

• Patients on hydroxyurea treatment are excluded (interference with glucose sensor readings).

Contacts and Locations

Locations

Italy

Federico II University Hospital

Naples, Italy, 80131

Sponsors and Collaborators

Federico II University

More Information

• Responsible Party: Giovanni Annuzzi, Associate professor, Federico II University
• ClinicalTrials.gov Identifier: NCT04871958
• Other Study ID Numbers: Initiator
• First Posted: May 4, 2021
• Last Update Posted: May 4, 2021
• Last Verified: April 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Giovanni Annuzzi, Federico II University:

Diabetes mellitus; Covid-19; Hospital care; Continuous glucose monitoring; Insulin pump; CGM metrics

Additional relevant MeSH terms:

COVID-19; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Respiratory Tract Infections; Infections; Pneumonia, Viral; Pneumonia; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Insulin; Hypoglycemic Agents; Physiological Effects of Drugs